A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. The decision was filed late on Wednesday in response to a lawsuit brought by a compounding industry group that challenged the U.